Tendai Mugwagwa

Tadworth, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.

Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.

Journal: Journal of medical economics

Published: September 04, 2026

Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.

Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.

Journal: Journal of medical economics

Published: July 06, 2026

Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.

Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.

Journal: Journal of medical economics

Published: June 13, 2026

Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review.

Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review.

Journal: Journal of medical economics

Published: October 24, 2025

Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis.

Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis.

Journal: Journal of medical economics

Published: July 25, 2025

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review.

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review.

Journal: BMC infectious diseases

Published: May 02, 2025

Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors.

Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors.

Journal: Journal of medical economics

Published: December 20, 2024

Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.

Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.

Journal: Cost effectiveness and resource allocation : C/E

Published: December 16, 2024

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.

Journal: Journal of medical virology

Published: November 28, 2024

Estimating hospitalization costs for Health Technology Appraisals (HTA) in England: a systematic literature review and best practice framework.

Estimating hospitalization costs for Health Technology Appraisals (HTA) in England: a systematic literature review and best practice framework.

Journal: Journal of medical economics

Published: November 19, 2024

Impact of patient's financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes.

Impact of patient's financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: September 30, 2024

Age-targeted vaccination for reducing Clostridioides difficile infection in England: a coupled mathematical-economic modelling analysis.

Age-targeted vaccination for reducing Clostridioides difficile infection in England: a coupled mathematical-economic modelling analysis.

Journal: BMC medicine

Published: September 09, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026